Mario Campone
Advertisement
Articles by Mario Campone
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer
ByMatthew P. Goetz, MD,Masakazu Toi,Jens Huober, MD,Joohyuk Sohn,Oliver Trédan,In Hae Park,Mario Campone,Shin-Cheh Chen,Luis Manuel Manso,Shani Paluch-Shimon,Orit C. Freedman,Joyce A. O’Shaughnessy,Xavier Pivot,Sara M. Tolaney, MD, MPH,Sara A. Hurvitz, MD,Antonio Llombart,Valérie André,Abhijoy Saha,Gertjan van Hal,Ashwin Shahir,Hiroji Iwata,Stephen R.D. Johnston
Advertisement
Latest Updated Articles
TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)Published: April 22nd 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel Vaccine Combo Shows Responses in Recurrent Epithelial Ovarian Cancer
2
Firmonertinib Demonstrates Promise in EGFR+ Advanced/Metastatic NSCLC
3
Relacorilant/Nab-Paclitaxel Meets OS End Point in Platinum-Resistant Ovarian Cancer
4
FDA Accepts NDA for Gedatolisib in HR+/HER2–, PIK3CA Wild-Type Breast Cancer
5